ImmTAC
ImmTAC (Immune mobilizing monoclonal T-cell receptors Against Cancer) are a novel class of biopharmaceuticals designed to treat cancer by harnessing the body's immune system. ImmTACs are engineered molecules that combine the specificity of monoclonal antibodies with the potent killing mechanism of T-cells.
Mechanism of Action[edit | edit source]
ImmTACs work by targeting cancer cells with high precision. They consist of two main components:
- A high-affinity T-cell receptor (TCR) that recognizes and binds to specific peptide-major histocompatibility complex (pMHC) complexes on the surface of cancer cells.
- An anti-CD3 single-chain variable fragment (scFv) that recruits and activates T-cells.
When an ImmTAC binds to a cancer cell, it brings a T-cell into close proximity with the cancer cell, leading to the activation of the T-cell. This results in the targeted killing of the cancer cell through the release of cytotoxic granules and the induction of apoptosis.
Development and Clinical Trials[edit | edit source]
ImmTACs are being developed by various biopharmaceutical companies. They are currently undergoing clinical trials to evaluate their safety and efficacy in treating different types of cancer, including melanoma, ovarian cancer, and lung cancer.
Advantages[edit | edit source]
ImmTACs offer several advantages over traditional cancer therapies:
- High specificity for cancer cells, reducing damage to healthy tissues.
- Ability to target intracellular antigens presented on the cell surface by MHC molecules.
- Potential to overcome immune evasion mechanisms employed by cancer cells.
Challenges[edit | edit source]
Despite their potential, ImmTACs face several challenges:
- The need for precise identification of suitable target antigens.
- Potential for off-target effects and toxicity.
- Complex manufacturing processes.
Related Pages[edit | edit source]
- Cancer immunotherapy
- Monoclonal antibody
- T-cell receptor
- Major histocompatibility complex
- Apoptosis
- Cytotoxic T cell
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD